Akero Therapeutics — Technical Presentation (March 2024)
23 slides from Akero Therapeutics's technical presentation, Mar 4, 2024
Slide 1: Phase 2b HARMONY Data Presentation: Topline Results from 96 Weeks of Efruxifermin
Exhibit 99.2 Restoring Balance. Renewing Life. Phase 2b HARMONY Data Presentation: Topline Results from 96 Weeks of Efruxifermin (EFX) Treatment in Patients with Pre-Cirrhotic MASH March 4, 2024
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation and the accompanying oral commentary may contain “forward‐looking statements” of AkeroTherapeutics, Inc. (“we,” “us,” “our,” “Akero” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, ope
Slide 3: Efruxifermin (EFX): A Bivalent Fc-FGF21 Fusion Protein
EFRUXIFERMIN (EFX): A Bivalent Fc-FGF21 Fusion Protein STATISTICALLY SIGNIFICANT EFFECTS AFTER 96 WEEKS ≥1 STAGE 2 STAGE FIBROSIS IMPROVEMENT MASH FIBROSIS FIBROSIS AND RESOLUTION MASH RESOLUTION IMPROVEMENT IMPROVEMENT ©2024 AKERO THERAPEUTICS. 3
Slide 4: HARMONY Trial Design: Pre-Cirrhotic (F2-F3) MASH with Liver Histology at 24 and 96 weeks
HARMONY Trial Design: Pre-Cirrhotic (F2-F3) MASH with Liver Histology at 24 and 96 weeks Week 96 Primary Analyses Week 24 Primary Endpoint •≥ 1 or 2 stages fibrosis improvement & no worsening of MASH •≥ 1 stage fibrosis improvement • MASH Resolution & No Worsening of Fibrosis & no worsening of MASH
Slide 5: Analysis Sets
Analysis Sets Analysis Set N Description Full Analysis Set 128 All randomized subjects Safety Set / Modified Full Analysis Set (ITT) 1 126 All randomized and dosed subjects Placebo (N=43) 28mg (N=40) 50mg (N=43) Week 24 Liver Biopsy Analysis Set 113 All subjects with baseline and Week 24 biopsy resu
Slide 6: Baseline Demographics
Baseline Demographics Placebo EFX 28mg EFX 50mg Parameter (Units) (N=43) (N=42) (N=43) Age (Years) 55 57 52 Sex (% Female) 63 69 53 Weight (kg) 108 104 103 Type 2 Diabetes (%) 65 76 70 1 Fibrosis Stage (% F3) 70 64 63 Proportion of Patients Treated with GLP-1 at Baseline (%) 21 18 9 Enhanced Liver F
Slide 7: ≥1 Stage Fibrosis Improvement & No Worsening of MASH: Statistically Significant Response for 50mg EFX at Week 96
≥1 Stage Fibrosis Improvement & No Worsening of MASH: Statistically Significant Response Observed for 50mg EFX at Week 96 Fibrosis Improvement ≥1 Stage & No Worsening of MASH at Week 96 1 Primary Analysis *** *** 80% 75% 60% 46% 40% 2 ITT Analysis Placebo EFX 28mg EFX 50mg 24% (N=43) (N=40) (N=43) 2
Slide 8: ≥1 Stage Fibrosis Improvement & No Worsening of MASH: Sustained, Broad and Durable Response
≥1 Stage Fibrosis Improvement & No Worsening of MASH: Sustained, Broad and Durable Response Fibrosis Improvement ≥1 Stage & No Worsening of MASH at Week 96 1 2 Sustained & New Responders Proportion of Week 24 Responders with *** *** 80% 75% 3,5 Sustained Response at Week 96 Placebo EFX 28mg EFX 50mg
Slide 9: EFX Fibrosis Improvement in Context: Pre-Cirrhotic MASH, ≥1 Stage
EFX Fibrosis Improvement in Context: Pre-Cirrhotic MASH: ≥1 Stage Improvement in Fibrosis & No Worsening of MASH Efruxifermin Pegozafermin Denifanstat Resmetirom Semaglutide Tirzepatide Survodutide Phase 2b (F2-F3) Phase 2b (F2-F3) Phase 2b (F2-F3) Phase 3 (F1-F3) Phase 2b (F2-F3) Ph2b (F2-F3) Ph 2b
Slide 10: 2 Stage Fibrosis Improvement & No Worsening of MASH: Significant Response for Both EFX Groups
2 Stage Fibrosis Improvement & No Worsening of MASH: Statistically Significant Response Observed for Both EFX Groups Fibrosis Improvement 2 Stages & No Worsening of MASH at Week 96 1 Primary Analysis 40% *** *** 36% ** ** 31% 30% 20% 2 ITT Analysis Placebo EFX 28mg EFX 50mg (N=43) (N=40) (N=43) 10%
Slide 11: EFX Fibrosis Improvement in Context: Pre-Cirrhotic MASH, ≥2 Stage
EFX Fibrosis Improvement in Context: Pre-Cirrhotic MASH: ≥2 Stage Improvement in Fibrosis & No Worsening of MASH Efruxifermin Resmetirom Semaglutide Phase 2b (F2-F3) Phase 3 (F1-F3) Phase 2b (F2-F3) 96 Wks / 66% F3 52 Wks / 62% F3 72 Wks / 69% F3 Consensus Readers Two Readers Consensus Readers 1 2 2
Slide 12: ≥1 Stage Fibrosis Improvement: Significant Response Among F3 Patients for 50mg EFX
≥1 Stage Fibrosis Improvement & No Worsening of MASH: Statistically Significant Response Among F3 Patients Observed for 50mg EFX Fibrosis Improvement ≥1 Stage & No Worsening of MASH at Week 96 1 F3 Fibrosis Subset *** *** 68% 2 Stages (n=8) 40% 2 Stages (n=5) 14% 1 Stage (n=5) 1 Stage (n=3) 1 Stage
Slide 13: MASH Resolution & No Worsening of Fibrosis: Significant Response for Both EFX Groups
MASH Resolution & No Worsening of Fibrosis: Statistically Significant Response Observed for Both EFX Groups MASH Resolution & No Worsening of Fibrosis at Week 96 1 Primary Analysis 70% ** ** 62% ** ** 60% 57% 50% 40% 2 ITT Analysis 30% 24% Placebo EFX 28mg EFX 50mg 20% (N=43) (N=40) (N=43) * * 19% 4
Slide 14: ≥1 Stage Fibrosis Improvement AND MASH Resolution: Significant Response for Both EFX Groups
≥1 Stage Fibrosis Improvement AND MASH Resolution: Statistically Significant Response Observed for Both EFX Groups Fibrosis Improvement ≥1 Stage AND MASH Resolution at Week 96 1 Primary Analysis 60% ** *** 54% 50% ** ** 42% 40% 30% 2 ITT Analysis Placebo EFX 28mg EFX 50mg 20% (N=43) (N=40) (N=43) 9%
Slide 15: Significant Reductions in Non-Invasive Markers Reflect Histological Improvement in Fibrosis
Statistically Significant Reductions in Non-Invasive Markers Reflect Histological Improvement in Fibrosis LS Mean Change From Baseline to Week 96 ELF Score Pro-C3 (ng/mL) (GEN2 ELISA) Liver Stiffness (kPa) 0.0 0 2 -0.1 -10 0 -0.2 -0.6 † -20 -2 -17 -0.4 -30 -4 * -4.0 -0.6 -40 -6 ††† ‐40 ** -0.7 -0.8
Slide 16: Significant Improvements in Markers of Liver Injury Sustained Through Week 96
Statistically Significant Improvements in Markers of Liver Injury Sustained Through Week 96 ALT AST LS Mean Percent Change from Baseline LS Mean Percent Change from Baseline Baseline: 50-63 U/L Baseline: 42-57 U/L 20% 20% 10% 10% 0% 0% -10% -10% ** *** -20% -20% * *** *** -30% -30% *** ** *** *** **
Slide 17: Treatment-Emergent Adverse Events (TEAE) From Baseline through Week 96
Treatment-Emergent Adverse Events (TEAE) From Baseline through Week 96 Placebo EFX 28mg EFX 50mg TEAE Overview (N=43) (N=40) (N=43) TEAE Leading to Death 0 (0%) 0 (0%) 0 (0%) a a b b Drug-Related Serious Adverse Events (SAEs) 0 (0%) 1 (2%) 1 (2%) c c d d e,f e,f Non-drug-related SAEs 4 (9%) 3 (8%) 6
Slide 18: Safety Overview
Safety Overview Blood Pressure • No statistical difference versus placebo in systolic & diastolic BP at week 96 Markers of Liver Function and Hemostasis 1 2 3 • Remained stable, including platelets, bilirubin, INR , MELD and CP score Progression to Cirrhosis • Balanced across dose groups Bone Minera
Slide 19: Improvement in Lipoprotein Profile After 96 Weeks
Improvement in Lipoprotein Profile After 96 Weeks LS Mean Change From Baseline to Week 96 (%) Triglyceride (% change) Non-HDL (% change) LDL (% change) HDL (% change) 15% 10% 10% 40% 8% 10% 5% *** 5% 5% 5% 30% 4% 3% 27% 3% 0% 0% * -5% 0% 20% 18% -2% -10% -2% -5% -15% -5% 10% *** -15% 5% -20% *** -20
Slide 20: Insulin Sensitivity Remains Significantly Improved after 96 Weeks of Treatment with 50mg EFX
Insulin Sensitivity Remains Significantly Improved after 96 Weeks of Treatment with 50mg EFX LS Mean Percentage Change From Baseline to Week 96 HOMA-IR (% change) C-Peptide (% change) Adiponectin (% change) 80% 10% 15% 7% 10% 8% ** 63% 0% 5% 60% 0% -10% -11% -2% 40% -5% † 28% -20% -10% 17% -15% 20%
Slide 21: Trend to Loss of Body Weight Maintained Over 96 Weeks of Treatment with 50mg EFX
Trend to Loss of Body Weight Maintained Over 96 Weeks of Treatment with 50mg EFX LS Mean Change From Baseline to Week 96 Body Weight (kg) 0 ‐0.3 -1 ‐1.5 -2 -3 † ‐3.5 -4 Placebo EFX 28mg EFX 50mg n=34 n=27 n=27 † p<0.05, versus baseline (MMRM) ©2024 AKERO THERAPEUTICS. Source Data: FAS, non-missing v
Slide 22: Take-Aways: 50mg EFX After 96 Weeks
Take-Aways: 50mg EFX After 96 Weeks Unprecedented Deep Broad Durable Advanced WEEK 24 FIBROSIS ≥1 STAGE 2 STAGE CONVERSION TO WEEK 96 IMPROVEMENT IMPROVEMENT IMPROVEMENT OF NON- FIBROSIS AMONG F3 1 2 3 IN FIBROSIS IN FIBROSIS RESPONDERS 4 5 RESPONSE PATIENTS *** *** 6 6 *** 75% vs. 24% 36% vs. 3% 63
Slide 23: Akero Therapeutics, South San Francisco, CA
AKERO THERAPEUTICS 601 Gateway Boulevard NASDAQ: AKRO Nasdaq: AKRO Suite 350 South San Francisco, CA 94080
Akero Therapeutics — Technical Presentation (March 2024) on 6ix